1. Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018; 14(5):279–289. PMID:
29593343.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012; 14(1):R22. PMID:
22284862.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol. 2014; 32(2):188–193. PMID:
24447373.
4. Khoo T, Limaye V. Biologic therapy in the idiopathic inflammatory myopathies. Rheumatol Int. 2019; 40(2):191–205. PMID:
31680207.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy. Front Oncol. 2018; 8:163. PMID:
29915719.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Kinch MS. An overview of FDA-approved biologics medicines. Drug Discov Today. 2015; 20(4):393–398. PMID:
25220442.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572–2581. PMID:
15201414.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017; 389(10083):2031–2040. PMID:
28342637.
9. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221–232. PMID:
20647199.
10. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007; 146(1):25–33. PMID:
17200219.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):1215–1226. PMID:
22231479.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Bang SY, Lee CK, Kang YM, Kim HA, Suh CH, Chung WT, et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis. 2012; 2012:565039. PMID:
23304457.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev. 2019; 18(5):542–548. PMID:
30844555.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017; 56(1):26–36. PMID:
27121778.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Yang JA, Lee SJ, Park JW, Kwon HM, Moon JY, Ko DJ, et al. Rituximab treatment for the patients with refractory inflammatory myopathy. J Rheum Dis. 2013; 20(5):303–309.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977; 56(4):255–286. PMID:
327194.
17. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344–347. PMID:
1090839.
18. Couderc M, Gottenberg JE, Mariette X, Hachulla E, Sibilia J, Fain O, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford). 2011; 50(12):2283–2289. PMID:
22019807.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015; 372(18):1734–1747. PMID:
25923553.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018; 14(5):269–278. PMID:
29651121.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Bernatsky S, Joseph L, Pineau CA, Bélisle P, Boivin JF, Banerjee D, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009; 68(7):1192–1196. PMID:
18713785.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Engel A. Myology: Basic and Clinical. New York, NY: McGraw-Hill Companies;1994.
23. Vattemi G, Mirabella M, Guglielmi V, Lucchini M, Tomelleri G, Ghirardello A, et al. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights. 2014; 5(3):77–85. PMID:
26000159.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984; 16(2):193–208. PMID:
6383191.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Grundtman C, Malmström V, Lundberg IE. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther. 2007; 9(2):208. PMID:
17389031.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology. 2005; 65(11):1782–1787. PMID:
16344523.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Greco M, García de Yébenes MJ, Alarcón I, Brandy-García AM, Rúa-Figueroa Í, Loza E, et al. Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. Ann Rheum Dis. 2019; 78(9):1291–1292. PMID:
30910990.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015; 17(12):72. PMID:
26515574.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, et al. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016; 15(10):983–993. PMID:
27491568.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Ladislau L, Arouche-Delaperche L, Allenbach Y, Benveniste O. Potential pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in immune-mediated necrotizing myopathies. Curr Rheumatol Rep. 2018; 20(9):56. PMID:
30074107.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Moghadam-Kia S, Oddis CV, Aggarwal R. Anti-MDA5 antibody spectrum in western world. Curr Rheumatol Rep. 2018; 20(12):78. PMID:
30382445.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017; 56(9):1492–1497. PMID:
28499006.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013; 65(11):2954–2962. PMID:
24037894.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017; 19(1):259. PMID:
29178913.
![crossref](/image/icon/bnr_ref_cross.gif)
35. Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006; 65(2):242–245. PMID:
16410528.
36. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013; 65(2):314–324. PMID:
23124935.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004; 50(7):2281–2290. PMID:
15248228.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012; 106(4):581–587. PMID:
22280877.
![crossref](/image/icon/bnr_ref_cross.gif)
39. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52(2):601–607. PMID:
15692974.
![crossref](/image/icon/bnr_ref_cross.gif)
40. Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016; 55(6):991–999. PMID:
26888854.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014; 66(3):740–749. PMID:
24574235.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Doyle TJ, Dhillon N, Madan R, Cabral F, Fletcher EA, Koontz DC, et al. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. J Rheumatol. 2018; 45(6):841–850. PMID:
29606668.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Barsotti S, Cioffi E, Tripoli A, Tavoni A, D'Ascanio A, Mosca M, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018; 70(2):78–84. PMID:
29976041.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology/European League against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017; 76(5):782–791. PMID:
28385804.
45. de Souza FH, Miossi R, de Moraes JC, Bonfá E, Shinjo SK. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol. 2018; 58(1):31. PMID:
30657080.
![crossref](/image/icon/bnr_ref_cross.gif)
46. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(2):613–620. PMID:
16447239.
![crossref](/image/icon/bnr_ref_cross.gif)